retatrutide type 2 diabetes trial results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Phase III retatrutide study demonstrates

Research highlights that a small percentage of women taking semaglutide experience menstrual changes

I have called both the doctors office and the pharmacy multiple times

However, other in vitro research using human liver microsomes shows that gymnema does not affect CYP3A4 activity

Preserving 10 pounds of muscle during weight loss maintains approximately 40 to 50 extra calories of daily expenditure

The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction

Summary: GLP-1 receptor agonists do not directly cause sweating, but some patients report changes in perspiration patterns due to indirect factors such as gastrointestinal side effects, hypoglycaemia when combined with other diabetes medications, or autonomic responses to nausea